Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma


A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)




This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

Study Status: Completed


Condition Intervention Phase
Carcinoma, Renal Cell
Metastases, Neoplasm
Drug: GTI-2040 Phase 1/Phase 2

Verified by Lorus Therapeutics January, 2008

Sponsored by: Lorus Therapeutics
Information provided by: Lorus Therapeutics identifier: NCT00056173

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site